With your consent we use Google Analytics and Microsoft Clarity (which records clicks, scrolling and mouse movement) to see how the site is used. You can change your choice at any time under Cookie settings. Learn more

Case Study · Multiple Sclerosis

60 sites needed.
76 delivered, 50% in under 7 days.

How AcceleTrial helped a large global pharma sponsor exceed site targets for a competitive Multiple Sclerosis trial on compressed timelines.

Resources/Case Studies/Multiple Sclerosis Study
Therapeutic AreaMultiple Sclerosis
CustomerLarge Global Pharma
Platform UsedAcceleTrial®
Sites Target / Delivered60 needed / 76 provided

The Challenge

A competitive indication.
Compressed timelines. High stakes.

The sponsor needed a large, qualified site network in Multiple Sclerosis, one of the most competitive therapeutic areas in clinical development, without sacrificing timeline integrity.

01
Site identification at scale in a crowded TA

The sponsor needed 60 interested clinical sites (40 to activate, 20 to hold as backup) in Multiple Sclerosis, a therapeutic area with intense competition for qualified investigators and patient populations.

02
Compressed timelines for CDAs and Feasibility Questionnaires

The team needed to communicate with a large volume of clinical sites and execute Confidentiality Disclosure Agreements and Feasibility Questionnaires on an accelerated schedule with no margin for delay.

03
Efficient, rapid site activation

Sites needed to be activated efficiently and quickly to meet or exceed the sponsor's targeted timelines. Every delay in activation created downstream risk for the overall trial schedule.

The Solution

AcceleTrial identified
76 pre-qualified sites

Using AcceleTrial, LINEA System identified 76 pre-qualified clinical sites with specific MS expertise and verified patient access. With the platform's workflow automation, 50% of sites completed CDAs and feasibility questionnaires in under 7 days.

Half of all sites completed both the Confidentiality Disclosure Agreement and Feasibility Questionnaire in under 7 days. The rapid FQ turnaround was the key driver that allowed the team to accelerate site selection and stay ahead of the sponsor's schedule.

Site Qualification Criteria
MS Clinical ExperienceTrial HistoryPatient AccessSpecific Expertise
AcceleTrial® | MS Study Performance
76
Sites IdentifiedPre-qualified with MS expertise and verified patient access
50%
CDAs and FQs Completed Under 7 DaysHalf of all sites cleared both documents in under a week
40
Sites SelectedSelected to date from LINEA's delivery, matching the activation target of 40
60
Sites RequestedTarget of 60 (40 to activate, 20 backup) exceeded with 76 sites

Outcomes

Targets exceeded.
Timeline compressed.

76
Sites Identified

76 pre-qualified MS sites delivered against a sponsor target of 60, providing both the full activation cohort and a strong backup pool.

50%
CDAs and FQs Under 7 Days

Half of all sites completed both the CDA and Feasibility Questionnaire within 7 days, materially compressing the site selection cycle.

40
Sites Selected

The sponsor selected 40 sites from LINEA's delivery to date, meeting the activation target of 40.

27%
Above Target Delivery

LINEA identified 27% more sites than the sponsor requested, providing strategic backup capacity in a highly competitive therapeutic area.

Get the Full Story

Download the case study
or see AcceleTrial live

Get the one-page PDF summary or request a personalized demo using your protocol and therapeutic area.